Business
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) (\"INVO\"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. (\"NAYA\"), a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, today jointly announced that following the closing of their pending merger, Dr. Peter Kash, Ed.D., MBA will join the combined company's Board of Directors as Vice Chairman.\n\n \n \n \n \n \n \n\n \n\"I am delighted to join NAYA Biosciences upon the closing of its public merger,\" commented Dr. Peter Kash. \"As an emerging leader in the growing Florida biosciences ecosystem, NAYA has a unique business model, with scalable revenue generation from its fertility business and disruptive clinical-stage therapeutics primed for pharma partnerships. I look forward to working closely with Daniel and his leadership team on their mission to accelerate the development and commercialization of life-changing therapies through agile leadership, access to public capital, and targeted acquisitions.\"\n\"We welcome Peter to NAYA's board as we close our public merger with INVO and prepare to execute an ambitious growth strategy,\" added Dr. Daniel Teper, Chairman and CEO of NAYA Biosciences. \"Peter's track record as an entrepreneur, banker, and investor will be a major asset for NAYA and we look forward to his contribution and impact accelerating our goal of increasing patient access to life-transforming therapies.\"\nDr. Kash has over 36 years of leadership experience in the biotech industry. He is currently the cofounder and Vice Chairman of TargImmune Therapeutics (Switzerland) and cofounder and Managing Director of Camelot BioCapital. He was formerly a cofounder and partner and Chairman of Two River Group and President of Riverbank Capital Securities, specializing in helping create and finance several biotech companies including Kite Pharma, Edgemont Pharmaceuticals, and Intercept Pharmaceuticals. He has cofounded more than a dozen biotech companies and coraised in excess of $2 billion in private/public financing, helping creating more than $20 billion in peak aggregate market value. Dr. Kash has worked on Wall Street for 30 years including at Shearson Lehman Hutton and Paramount C...